Darolutamide plus radiation for intermediate-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding darolutamide to standard radiation can better control intermediate-risk prostate cancer. It includes men whose cancer has spread nowhere else and who are newly diagnosed with “unfavorable intermediate risk” or progress to that risk group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have prostate cancer confirmed by biopsy/pathology
- Your scans show no spread to lymph nodes outside the area or to distant organs (no metastases)
- Your risk level is “unfavorable intermediate risk,” based on PSA, Gleason score, and/or tumor stage
- You can have radiation safely as judged by your doctor, and you can undergo MRI and contrast CT scans
- You are generally well enough for treatment (life expectancy at least 5 years, and performance status ECOG 0–2)
- You can give consent and agree to effective contraception during treatment and for 1 week after stopping
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
This Phase 2 trial tests whether adding darolutamide and degarelix to radiation can improve outcomes in men with intermediate-risk prostate cancer. If you fit the cancer and health criteria, it may offer a way to treat the cancer more aggressively than radiation alone.
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests darolutamide (a hormone blocker pill) with or without standard hormone therapy given before surgery for high-risk prostate cancer. The goal is to see if this combination can shrink the cancer and improve outcomes before the prostate is removed.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.